Cargando…
Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
Diabetic neuropathy (DN) is a frequent complication of diabetes mellitus (DM) with severe consequences as it progresses and influences all human body systems. This review discusses the risk factors for DN, the main characteristics of the clinical forms of DN, the screening methods and the current th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111877/ https://www.ncbi.nlm.nih.gov/pubmed/33986855 http://dx.doi.org/10.3892/etm.2021.10122 |
_version_ | 1783690581096005632 |
---|---|
author | Bondar, Andrei Popa, Amorin Remus Papanas, Nikolaos Popoviciu, Mihaela Vesa, Cosmin Mihai Sabau, Monica Daina, Cristian Stoica, Roxana Adriana Katsiki, Niki Stoian, Anca Pantea |
author_facet | Bondar, Andrei Popa, Amorin Remus Papanas, Nikolaos Popoviciu, Mihaela Vesa, Cosmin Mihai Sabau, Monica Daina, Cristian Stoica, Roxana Adriana Katsiki, Niki Stoian, Anca Pantea |
author_sort | Bondar, Andrei |
collection | PubMed |
description | Diabetic neuropathy (DN) is a frequent complication of diabetes mellitus (DM) with severe consequences as it progresses and influences all human body systems. This review discusses the risk factors for DN, the main characteristics of the clinical forms of DN, the screening methods and the current therapeutic options. Distal symmetric DN is the primary clinical form, and DM patients should be screened for this complication. The most important treatment of DN remains good glucose control, generally defined as HbA1c ≤7%. Symptomatic treatment improves life quality in diabetic patients. Pharmacological agents such as alpha (α)-lipoic acid and benfotiamine have been validated in several studies since they act on specific pathways such as increased oxidative stress (α-lipoic acid exerts antioxidant effects) and the excessive production of advanced glycosylation products (benfotiamine may inhibit their production via the normalization of glucose). Timely diagnosis of DN is significant to avoid several complications, including lower limb amputations and cardiac arrhythmias. |
format | Online Article Text |
id | pubmed-8111877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-81118772021-05-12 Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) Bondar, Andrei Popa, Amorin Remus Papanas, Nikolaos Popoviciu, Mihaela Vesa, Cosmin Mihai Sabau, Monica Daina, Cristian Stoica, Roxana Adriana Katsiki, Niki Stoian, Anca Pantea Exp Ther Med Review Diabetic neuropathy (DN) is a frequent complication of diabetes mellitus (DM) with severe consequences as it progresses and influences all human body systems. This review discusses the risk factors for DN, the main characteristics of the clinical forms of DN, the screening methods and the current therapeutic options. Distal symmetric DN is the primary clinical form, and DM patients should be screened for this complication. The most important treatment of DN remains good glucose control, generally defined as HbA1c ≤7%. Symptomatic treatment improves life quality in diabetic patients. Pharmacological agents such as alpha (α)-lipoic acid and benfotiamine have been validated in several studies since they act on specific pathways such as increased oxidative stress (α-lipoic acid exerts antioxidant effects) and the excessive production of advanced glycosylation products (benfotiamine may inhibit their production via the normalization of glucose). Timely diagnosis of DN is significant to avoid several complications, including lower limb amputations and cardiac arrhythmias. D.A. Spandidos 2021-07 2021-04-29 /pmc/articles/PMC8111877/ /pubmed/33986855 http://dx.doi.org/10.3892/etm.2021.10122 Text en Copyright: © Bondar et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Bondar, Andrei Popa, Amorin Remus Papanas, Nikolaos Popoviciu, Mihaela Vesa, Cosmin Mihai Sabau, Monica Daina, Cristian Stoica, Roxana Adriana Katsiki, Niki Stoian, Anca Pantea Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) |
title | Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) |
title_full | Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) |
title_fullStr | Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) |
title_full_unstemmed | Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) |
title_short | Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) |
title_sort | diabetic neuropathy: a narrative review of risk factors, classification, screening and current pathogenic treatment options (review) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111877/ https://www.ncbi.nlm.nih.gov/pubmed/33986855 http://dx.doi.org/10.3892/etm.2021.10122 |
work_keys_str_mv | AT bondarandrei diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT popaamorinremus diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT papanasnikolaos diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT popoviciumihaela diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT vesacosminmihai diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT sabaumonica diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT dainacristian diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT stoicaroxanaadriana diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT katsikiniki diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview AT stoianancapantea diabeticneuropathyanarrativereviewofriskfactorsclassificationscreeningandcurrentpathogenictreatmentoptionsreview |